Information Provided By:
Fly News Breaks for April 26, 2019
DOW
Apr 26, 2019 | 08:45 EDT
As previously reported, Argus initiated Dow Inc with a Hold rating, saying that while the company should "benefit over time from low cost structure, solid cash flow and declining capital spending requirements", its near term performance may be impacted by "increased production capacity and weaker global economic conditions." The analyst adds that a more constructive rating on Dow Inc would require a "significant nonfundamental pullback in the share price, slower growth in industry capacity, or stronger-than-expected global economic growth."
News For DOW From the Last 2 Days
DOW
Jun 17, 2019 | 11:24 EDT
Check out today's top analyst calls from around Wall Street, compiled by The Fly. SYMANTEC BOOSTED TO... To see the rest of the story go to thefly.com. See Story Here
DOW
Jun 17, 2019 | 10:12 EDT
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Disney (DIS) downgraded to In-Line from Outperform at Imperial Capital wite analyst David Miller citing valuation. 2. Dow Inc. (DOW) downgraded to Market Perform from Outperform at BMO Capital with analyst John McNulty saying that while the company remains among the "diversified pure-play-commodity companies in the space" with focus on shareholder value and led by "solid" management, its 2019 is looking increasingly challenging due to persisting global trade issues and faltering macro growth. 3. Endo (ENDP) downgraded to Neutral from Buy at Citi with analyst Liav Abraham stating she "cannot ignore the headwinds" associated with the company's opioid-related litigation. 4. LyondellBasell (LYB) downgraded to Hold from Buy at Deutsche Bank with analyst David Begleiter expecting shares to be range-bound through the end of 2019 amid questions into the "depth and duration" of the U.S. ethylene cycle downturn. 5. Ashford Hospitality (AHT) downgraded to Neutral from Buy at DA Davidson with analyst James Lykins noting the company's decision to halve its dividend raises a near-term uncertainty which, along with industry headwinds, warrants a move to the sidelines. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DOW
Jun 17, 2019 | 09:15 EDT
HIGHER: Array Biopharma (ARRY), up 59% after agreeing to be acquired by Pfizer (PFE) for $48.00 per share... Aclaris Therapeutics (ACRS), up 9% after announcing results from a Phase 2 open-label clinical trial of ATI-502, an investigational topical Janus Kinase 1/3 inhibitor, in patients with androgenetic alopecia... uniQure (QURE), up 8% after Bloomberg reported the company is exploring options with advisers, including a potential sale or partnerships, amid interest from companies looking to expand in gene therapy... Calithera Biosciences (CALA), up 8% after announcing results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat in combination with everolimus in patients with advanced renal cell carcinoma... Corteva (CTVA), up 1% after Deutsche Bank analyst David Begleiter upgraded the stock to Buy from Hold and raised his price target for the shares to $32 from $30... Mosaic (MOS), up 3% after BofA Merrill Lynch analyst Steve Byrne upgraded shares to Buy with a price target of $30. LOWER: Paysign (PAYS), down 4% after BTIG analyst Mark Palmer downgraded the stock to Neutral from Buy citing valuation... Endo (ENDP), down 4% after Citi analyst Liav Abraham downgraded shares to Neutral from Buy. While acknowledging the improvement in Endo's underlying business over the past couple of years, the analyst says one "cannot ignore the headwinds" associated with the company's opioid-related litigation... Dow Inc. (DOW), down 1% after BMO Capital Markets analyst John McNulty downgraded the stock to Market Perform from Outperform and lowered his price target for the shares to $52 from $58.